David Wild - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock David Wild's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
David Wild
Verified
Pharma and Biotech Reporter, In Vivo
Toronto
Beats
Content
By David Wild Verified| Citeline Verified BioBytes: AI-Related Deals In Q1 ‘25AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs. BioBytes Is In Vivo's AI-Focused Blog • Source: Shutterstock
By David Wild Verified| Citeline Verified Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis AssetNicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.
By David Wild Verified| Citeline Verified Podcast: OSE Immunotherapeutics’ CEO On Ulcerative Colitis AssetNicolas Poirier, CEO of French biotech OSE Immunotherapeutics, spoke with In Vivo about the company's anti-IL-7R antibody, lusvertikimab, on the heels of impressive ulcerative colitis data presented at the 2025 European Crohn's and Colitis Organization meeting.
Company Info
In Vivo
United Kingdom, United Kingdom